CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于脑肿瘤的 CAR-T 细胞生产
英文原题：Chimeric Antigen Receptor T Cell Production for Brain Cancers.
查看英文原题
Chimeric Antigen Receptor T Cell Production for Brain Cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞是经过工程化改造、能够特异性识别靶细胞上目标抗原的T细胞，这些靶细胞可能存在于癌症或其他病理状态中。迄今为止，CAR-T 细胞疗法仅获批用于血液系统恶性肿瘤，许多研究团队和试验正在致力于开发用于实体瘤的CAR-T 细胞。在此，我们描述了利用人外周血单个核细胞（PBMCs）和第三代包装载体进行CAR-T 细胞生产的概要流程，用于体外和体内实验检测。
展开英文摘要原文
Chimeric Antigen Receptor (CAR) T cells are T cells that have been engineered to specifically recognize antigens of interest on target cells, may that be in cancer or other pathologies. To date, CAR T cell therapy has solely been approved for use in liquid cancers, with many groups and trial working on CAR T cells for solid tumors.
Herein, we describe the outline CAR T cell production using human peripheral blood mononuclear cells (PBMCs) and third-generation packaging vectors for use in in vitro and in vivo experimental assays.
论文信息
- 作者
- Maich WT、Brakel B、Venugopal C、Singh SK
- 第一作者单位
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.Canada
- 通讯作者单位
- Department of Surgery, McMaster University, Hamilton, ON, Canada. ssingh@mcmaster.ca.Canada
- 期刊
- Methods in molecular biology (Clifton, N.J.)2025
- 原文标识
- PubMed 40553282 · DOI 10.1007/978-1-0716-4654-0_13